Abstract
Background: Short interfering RNAs (siRNAs) are double-stranded RNA molecules able to specifically targeting genes products responsible for human diseases. Cyclin D1 (CyD1) is a cell cycleregulatory molecule, up-regulated at sites of inflammation in several tissues. CyD1 is a very interesting potential target in lung and colon inflammatory diseases.
Objective: The aim of this paper was testing CyD1 expression in human lung and colon tissues after the application of an inflammatory stimulus, and verifying its gene silencing by using siRNA for CyD1 (siCyD1). Method: Colon and pulmonary biopsies were treated with siCyD1 by using two different transfection carriers: a) invivofectamine and b) ad hoc produced nanoliposomes. After 24 hours of incubation with nanoliposomes encapsulating siRNA or invivofectamine-CyD1siRNA, in presence or absence of ECLPS, we analysed the protein expression of CyD1 through Western-Blotting. Results: After EC-LPS treatment, in both colon and pulmonary biopsies, an overexpression of CyD1was found (about 64% and 40% respectively). Invivofectamine-CyD1 siRNA reduced the expression of CyD1 approximately by 46% compared to the basal condition, and by around 65% compared to EC-LPS treated colon samples. In lung, following in vivo fectamine siRNA silencing in the presence of EC-LPS, no reduction was observed. Ad hoc nanoliposomes were able to enter colon and lung tissues, but CyD1 silencing was reported in 2 colon samples out of 4 and no efficacy was demonstrated in the only lung sample we studied. Conclusion: The silencing of Cyclin D1 expression in vitro “organ culture” model is possible. Our preliminary results encourage further investigations, using different siRNA concentrations delivered by nanoliposomes.Keywords: Colon inflammation, CyD1ARDS, drug delivery, human tissue, IBD, siRNA.
Graphical Abstract
Current Drug Delivery
Title:Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures
Volume: 14 Issue: 2
Author(s): Ornella Piazza, Ilaria Russo, Sabrina Bochicchio, Anna Angela Barba, Gaetano Lamberti, Pio Zeppa, Vincenzo Di Crescenzo, Albino Carrizzo, Carmine Vecchione and Carolina Ciacci
Affiliation:
Keywords: Colon inflammation, CyD1ARDS, drug delivery, human tissue, IBD, siRNA.
Abstract: Background: Short interfering RNAs (siRNAs) are double-stranded RNA molecules able to specifically targeting genes products responsible for human diseases. Cyclin D1 (CyD1) is a cell cycleregulatory molecule, up-regulated at sites of inflammation in several tissues. CyD1 is a very interesting potential target in lung and colon inflammatory diseases.
Objective: The aim of this paper was testing CyD1 expression in human lung and colon tissues after the application of an inflammatory stimulus, and verifying its gene silencing by using siRNA for CyD1 (siCyD1). Method: Colon and pulmonary biopsies were treated with siCyD1 by using two different transfection carriers: a) invivofectamine and b) ad hoc produced nanoliposomes. After 24 hours of incubation with nanoliposomes encapsulating siRNA or invivofectamine-CyD1siRNA, in presence or absence of ECLPS, we analysed the protein expression of CyD1 through Western-Blotting. Results: After EC-LPS treatment, in both colon and pulmonary biopsies, an overexpression of CyD1was found (about 64% and 40% respectively). Invivofectamine-CyD1 siRNA reduced the expression of CyD1 approximately by 46% compared to the basal condition, and by around 65% compared to EC-LPS treated colon samples. In lung, following in vivo fectamine siRNA silencing in the presence of EC-LPS, no reduction was observed. Ad hoc nanoliposomes were able to enter colon and lung tissues, but CyD1 silencing was reported in 2 colon samples out of 4 and no efficacy was demonstrated in the only lung sample we studied. Conclusion: The silencing of Cyclin D1 expression in vitro “organ culture” model is possible. Our preliminary results encourage further investigations, using different siRNA concentrations delivered by nanoliposomes.Export Options
About this article
Cite this article as:
Piazza Ornella, Russo Ilaria, Bochicchio Sabrina, Barba Angela Anna, Lamberti Gaetano, Zeppa Pio, Crescenzo Di Vincenzo, Carrizzo Albino, Vecchione Carmine and Ciacci Carolina, Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures, Current Drug Delivery 2017; 14 (2) . https://dx.doi.org/10.2174/1567201813666160512150710
DOI https://dx.doi.org/10.2174/1567201813666160512150710 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
How Valid is Placebo in the Indian Setting?
Central Nervous System Agents in Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Loop Transverse Colostomy - A Modified Technique
Combinatorial Chemistry & High Throughput Screening Reflections on MicroRNAs in Chronic Pulmonary Disease: Looking into the miR-ror and Crystal Ball
Inflammation & Allergy - Drug Targets (Discontinued) The Biological Potentials of Indian Traditional Medicine, Curcumin for Treating Human Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Biology of Heme: Drug Interactions and Adverse Drug Reactions with CYP450
Current Topics in Medicinal Chemistry Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews Dendrimer-Based Nanosized MRI Contrast Agents
Current Pharmaceutical Biotechnology Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Computer Techniques for Drug Development from Thai Traditional Medicine
Current Pharmaceutical Design Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art
Current Cancer Therapy Reviews Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research